Trial Profile

A Phase I Study of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified γδ T Cells in Patients With Newly Diagnosed Glioblastoma Multiforme Receiving Maintenance Temozolomide Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INB-200 (Primary) ; Temozolomide; Temozolomide; Temozolomide
Indications Glioblastoma
Focus Adverse reactions; First in man

Most Recent Events

09 Jul 2026 According to an IN8bio media release, company expects to provide additional updates to the DeltEx DRI program in newly diagnosed GBM later this year.
09 Jul 2026 According to an IN8bio media release, results from this trial published in The Journal of Clinical Oncology (JCO).
09 Jul 2026 Results presented in an IN8bio Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com